Navigation Links
The Galien Foundation Debuts 2017 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories
Date:7/26/2017

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Alexion Pharmaceuticals Inc.

Kanuma® Alexion Pharmaceuticals Inc.

Strensiq® Amgen Inc.

IMLYGIC® Amgen Inc.

Repatha®Biogen & Ionis Pharmaceuticals

SPINRAZA™Boehringer Ingelheim

Praxbind®Eli Lilly and Company

CYRAMZA® Eli Lilly and Company

LARTRUVO™ Genentech, a Member of the Roche Group

Kadcyla®GlaxoSmithKline plc

Benlysta®Merck & Co., Inc.

Zinplava™Onyx Pharmaceuticals Inc. & Amgen Inc.

Blincyto®Pfizer Inc.

Trumenba®Regeneron and sanofi

PRALUENT®Sarepta Therapeutics, Inc.

EXONDYS 51™

Best Pharmaceutical Agent (Nominees)

AbbVie Inc.

Duopa™AbbVie Inc.

Technivie™AbbVie Inc.

Venclexta™ACADIA Pharmaceuticals Inc.

NUPLAZID®Allergan, Inc.

Dalvance®Allergan, Inc.

Kybella®Allergan, Inc.

Viberzi™Astellas

Cresemba®AstraZeneca

Lynparza®AstraZeneca

Tagrisso®Boehringer Ingelheim

Jardiance®Boehringer Ingelheim

OFEV®Bristol-Myers Squibb Company

Daklinza™Eisai Inc.

Halaven®Eisai Inc.

Lenvima®Endoceutics, Inc.

Intrarosa™Genentech, a Member of the Roche Group

Alecensa®Genentech, a Member of the Roche Group

Esbriet®Gilead

Harvoni®Helsinn Therapeutics Inc. & Eisai Inc.

Akynzeo®Iroko Pharmaceuticals, LLC

Vivlodex™Janssen Pharmaceutical Companies

DARZALEX™Janssen Pharmaceutical Companies

YONDELIS®Jazz Pharmaceuticals

Defitelio®LEO Pharma Inc.

Enstilar®Merck & Co., Inc.

Zepatier®Novartis

ZYKADIA®Otsuka Pharmaceutical Co., Ltd.

Rexulti®Pfizer Inc.

XELJANZ®Pfizer Inc. and Astellas

Xtandi®Shire plc

Xiidra®The Medicines Company

Orbactiv®UCB, Inc.

Briviact®Valeant

Jublia®

Best Medical Technology (Nominees)

Abbott

CardioMEMS™ HF SystemAllergan, Inc.

Juvederm Volbella® XCBiosense Webster

The THERMOCOOL SMARTTOUCH®, THERMOCOOL
SMARTTOUCH® Surround Flow Catheters and The CARTO
SMARTTOUCH™ Software Module    Boston Scientific

SpyGlass DS™ Direct Visualization System Boston Scientific

WATCHMAN™ Left Atrial Appendage Closure DeviceBrainScope Company, Inc.

BrainScope® OneINSIGHTEC

Exablate NeuroIntegra LifeSciences

Omnigraft™ Dermal Regeneration MatrixJohnson & Johnson - DePuy Synthes

ATTUNE® Knee SystemJohnson & Johnson - Ethicon

EVARREST® Fibrin Sealant PatchKoning Corporation

Koning Breast CT 1000

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2017-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300494168.html


'/>"/>
SOURCE The Galien Foundation
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
2. Boston Scientific Receives Prestigious 2013 Prix Galien Award For Best Medical Technology
3. The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
4. Stryker erhält prestigeträchtigen 2014 Prix Galien Award für die beste medizinische Technologie
5. Stryker reçoit le prestigieux Prix Galien 2014 pour la meilleure technologie médicale
6. The Galien Foundation Announces Partnership with Business France to Foster US-France Life Sciences Innovation via MedStartUp Program
7. The Prix Galien Russia Selection Committee Honors Excellence in Scientific Innovation at 2016 Prix Galien Russia Awards Gala
8. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
9. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
10. Betty Ford Center, Hazelden Foundation Pursue Possible Alliance
11. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):